Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO
Published
SAN DIEGO--(BUSINESS WIRE)--Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ: APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE: BAX) and The Boston Consulting Group. “We are excited
Full Article